…
BCAL Diagnostics Limited, a biotechnology company, engages in developing a novel blood screening test to support the early diagnosis and monitoring of breast cancer in Australia. It is involved in the development and commercialization of BREASTESTplus; Avantect Pancreatic; Avantect Ovarian; BREASTESTplus 2; BREASTEST Monitor; and Avantect multi-cancer test. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Bcal Diagnostics Ltd is an Australian-listed company developing and commercialising medical diagnostic tests. Long-term growth may be supported by regulatory approvals, successful clinical validation, commercial partnerships and uptake of its assays, and investors may find exposure to the diagnostics sector and potential intellectual property upside attractive.
Key risks include early-stage product and clinical/regulatory uncertainty, the need for additional funding to progress commercialisation, and competition from established diagnostics firms.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -9.54M | -7.24M | -9.45M | -5.06M | -3.39M |
| Net income | -7.37M | -7.24M | -6.40M | -5.06M | -3.39M |
| Selling general administrative | - | 5.12M | 1.64M | 3.27M | 1.87M |
| Selling and marketing expenses | - | 0.27M | 0.24M | - | 0.13M |
| Gross profit | -0.53M | 0.02M | 3.10M | - | - |
| Reconciled depreciation | - | 1.00M | 0.58M | 0.11M | 0.02M |
| Ebit | -9.39M | -7.20M | -6.03M | -4.73M | -3.91M |
| Ebitda | -8.67M | -6.19M | -5.67M | -7.78M | -3.89M |
| Depreciation and amortization | 0.72M | 1.00M | 0.36M | - | 0.02M |
| Operating income | -9.39M | -9.96M | -5.45M | -5.11M | -3.91M |
| Other operating expenses | 9.57M | 9.98M | 8.55M | - | 3.91M |
| Interest expense | 0.35M | 0.09M | 0.10M | - | 0.00M |
| Tax provision | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | - | 0.18M | 0.05M | 0.05M | 0.02M |
| Net interest income | - | 0.09M | -0.05M | 0.05M | 0.02M |
| Income tax expense | -2.17M | -2.63M | -3.05M | - | -0.02M |
| Total revenue | 0.18M | 0.02M | 3.10M | 2.79M | 0.72M |
| Total operating expenses | 8.86M | 9.98M | 8.55M | - | 3.91M |
| Cost of revenue | 0.72M | - | 0.58M | - | - |
| Total other income expense net | -0.15M | 2.72M | -4.00M | 2.79M | 0.51M |
| Net income from continuing ops | - | -7.24M | -6.40M | -5.06M | -3.39M |
| Net income applicable to common shares | - | -7.24M | -6.40M | -5.06M | -3.39M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 7.66M | 9.91M | 12.27M | 8.37M | 10.59M |
| Other current assets | 0.11M | - | 0.08M | -0.00M | 4.00M |
| Total liab | 8.49M | 3.69M | 3.68M | 3.16M | 0.95M |
| Total stockholder equity | -0.83M | 6.22M | 8.59M | 5.21M | 9.64M |
| Other current liab | 0.59M | - | 1.13M | 0.04M | 0.67M |
| Common stock | 34.01M | - | 28.90M | 19.28M | 18.87M |
| Capital stock | - | 33.83M | - | 19.28M | 18.87M |
| Retained earnings | -35.42M | -28.08M | -20.98M | -14.61M | -9.55M |
| Other liab | - | - | - | 0.00M | - |
| Other assets | - | - | 0.00M | - | - |
| Cash | 1.59M | 4.52M | 6.47M | 3.17M | 5.57M |
| Total current liabilities | 3.00M | 3.11M | 2.60M | 2.26M | 0.95M |
| Current deferred revenue | - | - | 0.28M | - | - |
| Net debt | 5.33M | - | -4.95M | - | -5.57M |
| Short term debt | 1.79M | - | 0.44M | 0.00M | 0.00M |
| Short long term debt | - | 1.58M | - | - | - |
| Short long term debt total | 6.92M | - | 1.52M | - | - |
| Other stockholder equity | - | - | - | 0.55M | 0.32M |
| Property plant equipment | - | - | - | 2.17M | 0.14M |
| Total current assets | 4.07M | 7.20M | 9.34M | 6.20M | 10.46M |
| Net tangible assets | - | - | - | 5.21M | 9.64M |
| Short term investments | - | - | - | 0.00M | 4.00M |
| Net receivables | 2.38M | - | 2.78M | 2.69M | 0.01M |
| Long term debt | - | 0.12M | - | - | 0.00M |
| Accounts payable | 0.63M | 0.55M | 0.74M | 1.58M | 0.28M |
| Accumulated other comprehensive income | 0.59M | - | 0.67M | - | 0.32M |
| Non currrent assets other | - | - | -0.00M | - | - |
| Non current assets total | 3.59M | 2.71M | 2.93M | 2.17M | 0.14M |
| Capital lease obligations | - | 0.68M | - | 1.06M | - |
| Long term debt total | - | - | - | 0.90M | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.79M | -1.15M | 4.00M | -4.00M |
| Change to liabilities | - | - | - | 0.78M | 0.05M |
| Total cashflows from investing activities | -1.44M | -0.79M | -1.15M | 3.64M | -4.03M |
| Net borrowings | - | 1.08M | -0.26M | -0.04M | -0.04M |
| Total cash from financing activities | 4.66M | 4.97M | 8.97M | 0.01M | 9.41M |
| Net income | -7.37M | -7.24M | -6.40M | -5.06M | -3.39M |
| Change in cash | -2.94M | -1.95M | 3.30M | -2.40M | 2.16M |
| Begin period cash flow | 4.52M | 6.47M | 3.17M | 5.57M | 3.41M |
| End period cash flow | 1.59M | 4.52M | 6.47M | 3.17M | 5.57M |
| Total cash from operating activities | -6.16M | -6.14M | -4.52M | -6.05M | -3.22M |
| Issuance of capital stock | - | 4.30M | 9.85M | 0.05M | 10.03M |
| Depreciation | 0.72M | - | 0.58M | 0.11M | 0.02M |
| Other cashflows from investing activities | -1.28M | - | - | 4.00M | -4.00M |
| Change to account receivables | 0.18M | 0.19M | 0.16M | -2.14M | -0.29M |
| Sale purchase of stock | - | -0.12M | -0.44M | 0.05M | -0.62M |
| Other cashflows from financing activities | 4.84M | -0.29M | -0.18M | 0.00M | -4.03M |
| Change to netincome | - | - | - | 0.27M | 0.38M |
| Capital expenditures | 0.46M | 0.79M | 1.15M | 0.36M | 4.03M |
| Change in working capital | -0.01M | -0.57M | 0.61M | 1.04M | 0.29M |
| Stock based compensation | - | - | 0.57M | - | - |
| Other non cash items | 0.50M | -5.56M | 0.11M | - | - |
| Free cash flow | -6.62M | -6.92M | -5.67M | -6.05M | -4.03M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BDX Bcal Diagnostics Ltd |
-0.00 1.64% |
0.06 | - | - | 9.40 | 10.18 | 150.40 | -1.80 |
| SHL Sonic Healthcare Ltd |
0.09 0.45% |
19.98 | 16.17 | 17.48 | 0.90 | 1.18 | 1.39 | 8.24 |
| ACL Australian Clinical Labs Ltd |
- -% |
3.35 | 27.92 | 17.45 | 0.85 | 4.18 | 1.29 | 5.31 |
| IDX Integral Diagnostics Ltd |
-0.01 0.90% |
1.65 | 27.75 | 15.85 | 0.79 | 0.92 | 1.48 | 9.23 |
| HLS Healius Ltd |
0.01 0.87% |
0.58 | - | 65.36 | 0.30 | 2.44 | 0.98 | 10.14 |
BCAL Diagnostics Limited, a biotechnology company, engages in developing a novel blood screening test to support the early diagnosis and monitoring of breast cancer in Australia. It is involved in the development and commercialization of BREASTESTplus; Avantect Pancreatic; Avantect Ovarian; BREASTESTplus 2; BREASTEST Monitor; and Avantect multi-cancer test. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
| Name | Title | Year Born |
|---|---|---|
| Ms. Jayne Andrea Shaw | Co-Founder & Exec. Chairman | NA |
| Dr. John G. Hurrell B.Sc, Fulbright Fel, M.Sc(Qual), Ph.D. | Chief Exec. Officer | NA |
| Hon. Ronald Anthony Phillips A.O. | Co-Founder & Non-Exec. Director | NA |
| Dr. Amani Batarseh Ph.D. | Chief Scientist Officer | NA |
| Mr. Guy Adrian Robertson B.Com., B.Comm(Hons.), C.A., CA, MAICD | CFO & Company Sec. | 1954 |
| Dr. Jane Ryan Bsc (Hons), M.A.I.C.D., Ph.D. | Chief Operating Officer | 1959 |
| Sean Kennedy | Director of Corp. Fin. | NA |
| Ms. Rebecca Shaw | Marketing Mang. | NA |
| Ms. Jayne Andrea Shaw | Co-Founder & Executive Chairman | NA |
| Ms. Jayne Andrea Shaw | Co-Founder & Executive Chairman | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.